Biotech Archives - Page 71 of 795

3 minute read

Ocuphire Pharma Announces First Patient Enrolled In LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) For The Treatment Of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

April 11, 10:05 AM

LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner ViatrisFARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage

OCUP

2 minute read

FibroBiologics Granted Patent For Regeneration Of Cartilage-Type Cells By The Australian Patent Office

By Benzinga Newsdesk

April 11, 9:32 AM

FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases

FBLG

2 minute read

Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher

By Vandana Singh

April 11, 9:27 AM

Rallybio partners with Johnson & Johnson to develop therapies targeting fetal and neonatal alloimmune thrombocytopenia, receiving $6.6 million investment. Phase 2 study for RLYB212 set for 2024.

JNJ

4 minute read

Candel Therapeutics Receives FDA Orphan Drug Designation For CAN-2409 For The Treatment Of Pancreatic Cancer

By Benzinga Newsdesk

April 11, 9:05 AM

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that

CADL

2 minute read

AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO’s Pay Package Boost

By Vandana Singh

April 11, 9:04 AM

AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CEO compensation proposal approaches vote. Recent acquisitions and FDA approvals signal growth.

AZN

2 minute read

Vertex Pharmaceutical’s Move Beyond Its $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune

By Vandana Singh

April 11, 9:01 AM

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to close Q2 2024. VRTX expanding into kidney disease treatment.

ALPN

4 minute read

Enlivex Announces Topline Results Of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

By Benzinga Newsdesk

April 11, 8:18 AM

Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the safety and efficacy topline analysis includes sequential organ failure assessment

ENLV

2 minute read

Bionano Announces Publication Showing That OGM Detects Over 1250 Structural Variants, Including 56 Gene Fusions, In Pediatric Leukemia That Were Missed By Whole Genome Sequencing

By Benzinga Newsdesk

April 11, 8:16 AM

Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping (OGM) to search for clinically and biologically relevant genomic

BNGO

3 minute read

Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive

By Benzinga Newsdesk

April 11, 8:15 AM

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 womenPivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrollingOvaprene has the potential to be the

DARE

2 minute read

Natera Announces Publication Of Largest Prospective dd-cfDNA Study In Kidney Transplantation

By Benzinga Newsdesk

April 11, 8:10 AM

ProActive study shows Natera's Prospera Kidney™ test detects rejection five months before biopsyNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from

NTRA